“We have been part of a comprehensive development team to ensure the NPC works and is practical for the medical teams who will use it,” said Lt. Col. Sarah Morton, AMC, chief, Aeromedical Evacuation Standards and Evaluation.
Ensuring the NPC was proven capable of what it was designed to do was a combined effort of the academia, contract partners, and Department of Defense units, including AF CBRN Defense, JPEO CBRND, AMC/A3, AMC/A5, AMC/SG, AMC/TE, AFOTEC Det-2, 28 TES, CCDC CBC and many more.
“The entire team from the program office, test teams, aeromedical users, scientific experts and MAJCOM representatives crossed common barriers to bring this capability to reality in epic time,” said Capt. Alexis Todaro, NPC program manager. “I’ve never seen so much effort put into pushing a product that can be used to save lives and meet what the Air Force needs.”
“While this was only an observational event for AFOTEC, we were able to capitalize on the opportunity and inject some realism by having flight physiologists in the NPC,” added Capt. Dustin Taylor from AFOTEC. “This event will also help shape our OUE [operational use evaluation] on the Phase II NPC.”
AMC has agreed with the PEO ACS led team’s recommendation to proceed with the NPC program based on the demonstrated proof of concept. The team will work required design changes to ensure production units meet certification requirements.
The NPC is an isolation prototype designed to fit on a C-17 or C-5. It has 28 seats for passengers, 24 seats for ambulatory patients that can be put up to hold eight litters, or combinations thereof. Designed in response to COVID-19, the NPC can safely isolate infected or potentially infected individuals while protecting the aircrew and not contaminating the aircraft. To learn more about the NPC and what it is designed to do, read more at
For more information about the development and proof of concept of the NPC, contact AFLCMC Public Affairs at AFLCMC.PA.Personnel@us.af.mil.